bio-amoksiklav 1000 tablet
biotech laboratories (pty) ltd - tablet - see ingredients - each tablet contains amoxycillin trihydrate equivalent to amoxycillin 875,0 mg potassium clavulanate equivalent to clavulanic acid 125,0 mg
ranclav 1 g tablet
ranbaxy (sa) (pty) ltd - tablet - see ingredients - each tablet contains amoxycillin trihydrate equivalent to amoxycillin 875,0 mg potassium clavulanate equivalent to clavulanic acid 125,0 mg
bindoclav 1000 mg tablet
actor pharma (pty) ltd - applicant - tablet - see ingredients - each tablet contains amoxycillin trihydrate equivalent to amoxycillin 875,0 mg potassium clavulanate equivalent to clavulanic acid 125,0 mg
auro-amoxiclav 1000 mg tablet
aurogen south africa (pty) ltd - tablet - see ingredients - each tablet contains amoxycillin trihydrate equivalent to amoxycillin 875,0 mg potassium clavulanate equivalent to clavulanic acid 125,0 mg
betaclav 1000 tablet
unicorn pharmaceuticals (pty) ltd - tablet - see ingredients - each tablet contains amoxycillin trihydrate equivalent to amoxycillin 875,0 mg potassium clavulanate equivalent to clavulanic acid 125,0 mg
ratio-aclavulanate tablet
teva canada limited - clavulanic acid (potassium clavulanate); amoxicillin (amoxicillin trihydrate) - tablet - 125mg; 500mg - clavulanic acid (potassium clavulanate) 125mg; amoxicillin (amoxicillin trihydrate) 500mg - aminopenicillins
ratio-aclavulanate tablet
teva canada limited - clavulanic acid (clavulanate potassium); amoxicillin (amoxicillin trihydrate) - tablet - 125mg; 875mg - clavulanic acid (clavulanate potassium) 125mg; amoxicillin (amoxicillin trihydrate) 875mg - aminopenicillins
noroclav 50 mg tablets for dogs and cats
norbrook laboratories australia pty limited - amoxycillin as amoxycillin trihydrate; clavulanic acid as potassium clavulanate - oral tablet - amoxycillin as amoxycillin trihydrate antibiotic active 40.0 mg/tb; clavulanic acid as potassium clavulanate antibiotic active 10.0 mg/tb - antibiotic & related - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - bacterial infection | bacterial skin disease | bordetella bronchiseptica | corynebacteria | dental infection | enteritis | escherichia coli (e. coli) | infections of the urinary tracts | klebsiella spp. | pasteurella spp. | proteus spp. | pyoderma | respiratory cond. - constricted airways | salmonella | soft tissue infections | staphylococci | streptococci | abscesses | airway constriction | amoxycillin sensitive bacteria | anal sacculitis | associated with viral disease | canine cough syndrome | constriction of airways | escherichia coli | gingivitis | gram negative organisms | gram positive organisms | group d streptococcus | including b-lactamase producin | infectious tracheobronchitis | klebsiella spp. | pasterellosis | pasteurellosis | post parturient bacterial infe | post-parturient infections | primary bacterial infection | proteus spp. | pseudomonas aeruginosa | pyoderma | salmonellosis | septicaemia | staphylococcus spp. | sulfadiazine sensitive bacteri | trimethoprim sensitive bacteri | tylosin sens
amoxiclav juno 500/100 amoxicillin (as sodium) 500 mg and clavulanic acid (as potassium clavulanate) 100mg powder for injection vial
juno pharmaceuticals pty ltd - amoxicillin sodium, quantity: 530.1 mg; potassium clavulanate, quantity: 119.13 mg - injection, powder for - excipient ingredients: - amoxiclav juno is an antibiotic alternative to narrow spectrum and broad-spectrum antibiotics for the treatment of polymicrobial infections; especially in mixed gram negative and gram positive infections, and situations where microbial confirmation has not yet been obtained. infections caused by amoxicillin susceptible organisms are amenable to amoxiclav juno treatment due to its amoxicillin content. infections caused by ?-lactamase producing amoxicillin resistant organisms are also amenable to amoxiclav juno due to its clavulanic acid content. susceptibility to amoxiclav juno will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. amoxicillin/clavulanic acid should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data. amoxiclav juno is indicated for the short term treatment of serious bacterial infections such as: ? ? upper respiratory tract infections (including ent): e.g. mastoiditis, tonsillitis, otitis media, epiglotitis and sinusitis when accompanied by severe signs and symptoms ? lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar, broncho-pneumonia and community acquired pneumonia ? genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, , female genital infections ? gastrointestinal infections ? e.g. intra-abdominal sepsis, peritonitis. ? skin and skin structure infections, in particular cellulitis, animal bites, diabetic foot infections, vascular surgery infection/ischaemic soft tissue infection, severe dental abscess ? other infections e.g. septic abortion, puerperal sepsis, post-surgical infections. ? ? amoxiclav juno is indicated for prophylaxis against infection in major surgical procedures that may be associated with higher risk of infectious complications eg. gastronitestinal surgery.
amoxiclav juno 1000/200 amoxicillin (as sodium) 1000 mg and clavulanic acid (as potassium clavulanate) 200mg powder for injection vial
juno pharmaceuticals pty ltd - amoxicillin sodium, quantity: 1060.2 mg (equivalent: amoxicillin, qty 1000 mg); potassium clavulanate, quantity: 238.25 mg (equivalent: clavulanic acid, qty 200 mg) - injection, powder for - excipient ingredients: - amoxiclav juno is an antibiotic alternative to narrow spectrum and broad-spectrum antibiotics for the treatment of polymicrobial infections; especially in mixed gram negative and gram positive infections, and situations where microbial confirmation has not yet been obtained. infections caused by amoxicillin susceptible organisms are amenable to amoxiclav juno treatment due to its amoxicillin content. infections caused by ?-lactamase producing amoxicillin resistant organisms are also amenable to amoxiclav juno due to its clavulanic acid content. susceptibility to amoxiclav juno will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. amoxicillin/clavulanic acid should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data. amoxiclav juno is indicated for the short term treatment of serious bacterial infections such as: ? upper respiratory tract infections (including ent): e.g. mastoiditis, tonsillitis, otitis media, epiglotitis and sinusitis when accompanied by severe signs and symptoms ? lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar, broncho-pneumonia and community acquired pneumonia ? genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, , female genital infections ? gastrointestinal infections ? e.g. intra-abdominal sepsis, peritonitis. ? skin and skin structure infections, in particular cellulitis, animal bites, diabetic foot infections, vascular surgery infection/ischaemic soft tissue infection, severe dental abscess ? other infections e.g. septic abortion, puerperal sepsis, post-surgical infections. ? amoxiclav juno is indicated for prophylaxis against infection in major surgical procedures that may be associated with higher risk of infectious complications eg. gastronitestinal surgery.